On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Research peptide with major gaps in human evidence.
Transport and signaling
PepT1-mediated uptake was associated with reduced NF-κB and MAP kinase pathway activity in the experimental cells. [1]
What the evidence shows
Intestinal-cell research
Investigators examined uptake through the PepT1 transporter in intestinal epithelial and immune cells. KPV reduced inflammatory signaling in those laboratory systems. [1]
Mouse colitis experiments
Oral KPV reduced inflammatory measures in two chemically induced mouse colitis models. These are experimental models rather than clinical trials of inflammatory bowel disease. [1]
What remains unknown
The work does not establish relief of human gut symptoms, healing of intestinal disease, or safe combinations with prescribed immunosuppressants.
Safety
Human safety gap
FDA reports that it has not identified human exposure data for KPV products, leaving important safety questions unanswered. [2]
Formulation limits
The mouse experiment supplied KPV in drinking water. It does not validate human capsules, injections, or a reconstitution method. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Can laboratory anti-inflammatory activity replace my gut diagnosis?
No. Similar symptoms can have different causes, and a cell-signaling result does not identify the cause of a person’s symptoms.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation2008 · Primary research · PubMed
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · Compound-specific safety assessment
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.